Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intermittent self-catheterisation in MS.
Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations.
Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
Revimmune (High-Dose Cyclophosphamide) for Autoimmune Diseases
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
ARESTIN®
Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators.
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Translating state-of-the-art spinal cord MRI techniques to clinical use: A systematic review of clinical studies utilizing DTI, MT, MWF, MRS, and fMRI.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Inflammation-induced fatigue: Exploring neurobiological mechanisms and potential treatments
Daclizumab Therapy for Multiple Sclerosis.
[The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.

Pages